Tuberville Presses Experts on China's Grip Over U.S. Drug Supply in Senate Hearing

U.S. Sen. Tommy Tuberville (R‑Alabama) sharply questioned pharmaceutical and national‑security experts this week during a Senate Committee on Aging hearing, raising alarms about what he called China's "death grip" on America's drug supply chain. The exchange underscored growing bipartisan concern that the United States is dangerously dependent on foreign manufacturing for essential medicines.

"It's becoming common knowledge that for whatever reason, China's often able to circumvent the FDA when producing generic medications worldwide," said Sen. Tuberville. "That means, Americans are often taking drugs that, if produced in the United States, would meet higher standards. How can we move that leverage that China has over our people making drugs?”

The hearing focused on the vulnerability created by China's dominance in producing key starting materials and active pharmaceutical ingredients (APIs)-the building blocks of most generic drugs used in U.S. hospitals, pharmacies, and emergency stockpiles.

A Stark Warning From Witnesses

Tuberville opened his questioning by pressing author and pharmaceutical‑supply‑chain expert Rosemary Gibson, who testified that China controls roughly 90% of the materials needed to make many generic drugs. When Tuberville asked what would happen if China cut off exports, Gibson did not mince words:

"A lot of people would die in this country. Our healthcare systems would cease to function."

Gibson argued that the U.S. is effectively importing "de facto unregulated products," because the FDA cannot reliably inspect or obtain data from Chinese manufacturers. She urged the federal government to use Department of Defense quality‑testing data to block low‑standard producers from the U.S. market.

National Security Concerns Take Center Stage

Tuberville then turned to foreign‑policy analyst Gordon Chang, who testified that China's pharmaceutical dominance is not accidental but strategic. Chang warned that the U.S. faces a period of "extreme vulnerability" within the next two to three years if it does not act.

Tuberville asked how the federal government should respond. Chang recommended:

- Emergency‑level action to rebuild domestic manufacturing

- Use of Section 232 tariffs to counter China's pricing advantage

- Expanded investment tax credits for U.S. drug‑production facilities

- Potential use of the Defense Production Act to accelerate onshore production

Chang said China has "outmaneuvered" the FDA and now holds leverage over the U.S. that could become a national‑security threat.

Tuberville Highlights His Drug‑Labeling Push

Tuberville used the hearing to promote the Clear Labels Act, legislation he supports alongside fellow Alabama Sen. Katie Britt. The bill would require drug labels to clearly disclose the country of origin for all ingredients-something Tuberville argues Americans deserve to know.

He told witnesses that transparency is essential for rebuilding trust and reducing dependence on foreign suppliers.

Why This Matters for Alabama

Alabama's hospitals, rural clinics, and pharmacies rely heavily on generic drugs-many of which originate in China. Shortages of antibiotics, cancer drugs, and sterile injectables have already strained providers across the state.

Tuberville framed the issue as both a national‑security threat and a public‑health risk, saying the U.S. cannot allow a geopolitical rival to control the supply of lifesaving medications.

What Comes Next

The Senate Committee on Aging is expected to continue examining pharmaceutical‑supply vulnerabilities throughout 2026. Tuberville has signaled he will push for:

- More aggressive FDA oversight

- Incentives for U.S.‑based drug manufacturing

- Greater transparency for consumers and healthcare providers

The hearing reflects a broader shift in Congress toward treating pharmaceutical supply chains as a strategic priority, not just an economic one.